Skip to content

Safety and efficacy of esketamine in epidural painless delivery

Safety and efficacy of esketamine in epidural painless delivery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061896
Enrollment
Unknown
Registered
2022-07-09
Start date
2022-06-30
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless delivery

Interventions

Group of low-dose esketamine:Ropacaine 100 mg+Esketamine 50 mg
Group of high-dose esketamine:Ropacaine 100 mg+Esketamine 100 mg
Group of Sufentanil:Ropacaine 100 mg+Sufentanil 50 ug

Sponsors

Qilu Hospital of Shandong University Dezhou Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. ASA I level, willing to give birth without pain; 2. The mother is a singleton, head position, no head-pelvic disproportion; 3. Height > 1.5 m, gestational period 38-42 weeks; 4. No coagulation dysfunction, no history of mental illness.

Exclusion criteria

Exclusion criteria: 1. Those with known allergy to ketamine; 2. Patients with intellectual disabilities; 3. Those who have a history of surgery or are receiving other analgesics and hormone therapy; 4. Those who are taking drugs that have the same pharmacological effect or interact with ketamine; 5. Those with nervous system or neuromuscular dysfunction; 6. Those with mental illness; 7. Before this study, there is a history of exposure to psychotropic drugs, alcohol, and tobacco products for more than 2 weeks.

Design outcomes

Primary

MeasureTime frame
Analgesia score;Fetal score;Depression score;nausea;

Secondary

MeasureTime frame
Sports score;

Countries

China

Contacts

Public ContactNiu Li

Qilu Hospital of Shandong University, Dezhou Hospital

niceli2009@163.com+86 15589192852

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026